The Effects of a CCR3 Inhibitor, AXP1275, on Allergen ‐Induced Airway Responses in Adults with Mild‐to‐Moderate Atopic Asthma

Conclusions & Clinical RelevanceAXP1275 50 mg administered daily was safe and well tolerated, and there was no difference in the type, severity, or frequency of treatment‐emergent adverse events in subjects while receiving AXP1275 compared to placebo. AXP1275 increased the methacholine PC20 however the low and variable exposure to APX1275 over a short treatment period may have contributed to poor efficacy on other outcomes.This article is protected by copyright. All rights reserved.
Source: Clinical and Experimental Allergy - Category: Allergy & Immunology Authors: Tags: Original Article ‐Experimental Models of Allergic Disease Source Type: research